Point Therapeutics Inc. has initiated a phase 2 clinical trial of the company's lead therapeutic compound, talabostat (PT-100), for treatment of advanced metastatic melanoma.
Addressing Disparities in Skin-Aging Prevention Among Women of Color
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Upadacitinib Outperforms Dupilumab in Primary and Secondary End Points in Head-to-Head AD Study
ReV Up Your Vitiligo Treatment Strategies
Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients
Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers